Soluble CTLA-4 in autoimmune thyroid diseases: Relationship with clinical status and possible role in the immune response dysregulation

Clinical Immunology

Volumn 123, Issue 2, 2007, Pages 190-198

  Saverino, Daniele ^a   Brizzolara, Renata ^b   Simone, Rita ^a   Chiappori, Alessandra ^b   Milintenda Floriani, Francesca ^a   Pesce, Giampaola ^b   Bagnasco, Marcello ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b Medical and Radiometabolic Therapy Unit   (Italy)

Author keywords

Autoimmunity; CTLA 4; Thyroid disease

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; THYROID HORMONE;

ADULT; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; B LYMPHOCYTE ACTIVATION; BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; CTLA 4 GENE; ENDOCRINE OPHTHALMOPATHY; FEMALE; GENE; GENE LOCUS; GENETIC SUSCEPTIBILITY; GRAVES DISEASE; HUMAN; HUMAN CELL; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNE RESPONSE; IMMUNOREGULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MIXED LYMPHOCYTE REACTION; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; THYROID DISEASE;

ADULT; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CELL LINE, TRANSFORMED; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MIDDLE AGED; MODELS, IMMUNOLOGICAL; PROTEIN BINDING; T-LYMPHOCYTES; THYROID DISEASES; THYROTOXICOSIS; TIME FACTORS;

EID: 34247092493     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.01.003     Document Type: Article

References (39)

1. Lenschow D.J., Walunas T.L., and Blueston J.A. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14 (1996) 233-258
2. Brunet J.F., Denizot F., Luciani M.F., Roux-Dosseto M., Suzan M., Mattei M.G., and Golstein P. A new member of the immunoglobulin superfamily: CTLA-4. Nature 328 (1987) 267-270
3. Linsley P.S., Brady W., Grosmaire L., Aruffo A., Damle N.K., and Ledbetter J.A. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173 (1991) 721-730
4. Linsley P.S., Brady W., Urnes M., Grosmaire L.S., Damle N.K., and Ledbetter J.A. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174 (1991) 561-569
5. Thompson C.B., and Allison J.P. The emerging role of CTLA-4 as an immune attenuator. Immunity 7 (1997) 445-450
6. Walunas T.L., Lenschow D.J., Bakker C.Y., Linsley P.S., Freeman G.J., Green J.M., Thompson C.B., and Bluestone J.A. CTLA-4 can function as a negative regulator of t cell activation. Immunity 1 (1994) 405-413
7. Krummel M.F., and Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182 (1995) 459-465
8. Saverino D., Tenca C., Zarcone D., et al. CTLA-4 (CD152) inhibits the specific lysis mediated by human cytolytic T lymphocytes in a clonally distributed fashion. J. Immunol. 162 (1999) 651-658
9. Waterhouse P., Penninger J.M., Timms E., et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270 (1995) 985-988
10. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., and Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3 (1995) 541-547
11. Pioli C., Gatta L., Ubaldi V., and Doria G. Inhibition of IgG1 and IgE production by stimulation of the B cell CTLA-4 receptor. J. Immunol. 165 (2000) 5530-5536
12. Merlo A., Tenca C., Fais F., Battini L., Ciccone E., Grossi C.E., and Saverino D. Inhibitory receptors CD85j, LAIR-1, and CD152 down-regulate immunoglobulin and cytokine production by human B lymphocytes. Clin. Diagn. Lab. Immunol. 12 (2005) 705-712
13. Karandikar N.J., Vanderlugt C.L., Walunas T.L., Miller S.D., and Bluestone J.A. CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med. 184 (1996) 783-788
14. Luhder F., Hoglund P., Allison J.P., Benoist C., and Mathis D. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune disease. J. Exp. Med. 187 (1998) 427-432
15. Yanagawa T., Hidaka Y., Guimaraes V., Soliman M., and DeGroot L.J. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J. Clin. Endocrinol. Metab. 80 (1995) 41-45
16. Nistico L., Buzzetti R., Pritchard L.E., et al. The CTLA-4 gene region of chromosome 2q33 is linked to and associated with type 1 diabetes. Hum. Mol. Genet. 5 (1996) 1075-1080
17. Donner H., Rau H., Walfish P.G., et al. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 82 (1997) 143-146
18. Marron M.P., Raffel L.J., Garchon H.J., et al. Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum. Mol. Genet. 6 (1997) 1275-1282
19. Kosta K., Watson P.F., and Weetman A.P. A CTLA-4 gene polymorphism is associated with both Graves' disease and autoimmune hypothyroidism. Clin. Endocrinol. 46 (1997) 551-555
20. Kemp E.H., Ajjan R.A., Husebye E.S., et al. A cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism is associated with autoimmune Addisons' disease in English patients. Clin. Endocrinol. 49 (1998) 609-613
21. Ueda H., Howson J.M., Esposito L., et al. Association of the T-cell regulatory gene CTLA-4 with susceptibility to autoimmune disease. Nature 423 (2003) 506-511
22. Oaks M.K., Hallett K.M., Penwell R.T., Stauber E.C., Warren S.J., and Tector A.J. A native soluble form of CTLA-4. Cell. Immunol. 201 (2000) 144-153
23. Magistrelli G., Jeannin P., Herbault N., de Colgnac A.B., Gauchat J.F., Bonnefoy J.Y., and Delneste Y. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur. J. Immunol. 29 (1999) 3596-3602
24. Oaks M.K., and Hallett K.M. A soluble form of CTLA-4 in patients with autoimmune thyroid disease. J. Immunol. 164 (2000) 5015-5018
25. Purohit S., Podolsky R., Collins C., et al. Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes. J. Autoimmun. Dis. 31 (2005) 2-8
26. Sato S., Fujimoto M., Hasegawa M., Komura K., Yanaba K., Hayakawa I., Matsushita T., and Takehara K. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology 43 (2004) 1261-1266
27. Wong C.K., Lit L.C.W., Tam L.S., Li E.K., and Lam C.W.K. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology 44 (2005) 989-994
28. Wang X.B., Kakoulidou M., Giscombe R., Qiu Q., Huang D., Pirskanen R., and Lefvert A.K. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J. Neuroimmunol. 130 (2002) 224-232
29. Wong C.K., Lun S.W.M., Ko F.W.S., Ip W.K., Hui D.S.C., and Lam C.W.K. Increased expression of plasma and cell surface co-stimulatory molecules CTLA-4, CD28 and CD86 in adult patients with allergic asthma. Clin. Exp. Immunol. 141 (2005) 122-129
30. Saverino D., Merlo A., Bruno S., Pistoia V., Grossi C.E., and Ciccone E. Dual effect of CD85/leukocyte Ig-like receptor-1/Ig-like transcript 2 and CD152 (CTLA-4) on cytokine production by antigen-stimulated human T cells. J. Immunol. 168 (2002) 207-215
31. Chiovato L., Fiore E., Vitti P., Rocchi R., Rago T., Dokic D., Latrofa F., Mammoli C., Lippi F., Ceccarelli C., and Pinchera A. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J. Clin. Endocrinol. Metab. 83 (1998) 40-46
32. Schall T.J., Lewis M., Koller K.J., et al. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 61 (1990) 361-370
33. Josimovic-Alasevic O., Herrmann T., and Diamenstein T. Demonstration of two distinct forms of released low-affinity type interleukin 2 receptors. Eur. J. Immunol. 18 (1998) 1855-1857
34. Mosley B., Beckmann M.P., March C.J., et al. The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms. Cell 59 (1989) 335-348
35. Goodwin R.G., Friend D., Ziegler S.F., et al. Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. Cell 60 (1990) 941-951
36. Cheng J., Zhou T., Liu C., Shapiro J.P., Brauer M.J., Kiefer M.C., Barr P.J., and Mountz J.D. Protection from Fas-mediated apoptosis by a soluble from of the Fas molecule. Science 263 (1994) 1759-1762
37. Fernandez-Botran R. Soluble cytokine receptors: their role in immunoregulation. FASEB J. 5 (1991) 2567-2574
38. Margolick J.B., Weetman A.P., and Burman K.D. Immunohistochemical analysis of intrathyroidal lymphocytes in Graves' disease: evidence of activated T cells and production of interferon-gamma. Clin. Immunol. Immunopathol. 47 (1988) 208-218
39. Battifora M., Pesce G., Paolieri F., et al. B7.1 costimulatory molecule is expressed on thyroid follicular cells in Hashimoto's thyroiditis, but not in Grave's disease. J. Clin. Endocrinol. Metabol. 83 (1998) 4130-4139